Year: 2025

– Company generated quarterly sequential growth in YCANTH® dispensed applicator units of 12.3% in Q4’24 concurrent with significantly lower operating expenses – – Company reports positive quarterly revenue earlier than previously disclosed expectations, as new demand resulted in Company’s primary distribution partner ordering applicators of YCANTH during Q4’24 – – Late-stage pipeline continues to advance with programs in basal cell carcinoma (VP-315) and common warts (VP-102/YCANTH) – – Recently strengthened balance sheet with the November 2024 $42 million public offering – – Conference call scheduled for today at 4:30 pm ET – WEST CHESTER, Pa., March 11, 2025 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...

Announces Extension of Existing Share Repurchase Plan DENVER, March 11, 2025 (GLOBE NEWSWIRE) — Concrete Pumping Holdings, Inc. (Nasdaq: BBCP) (the “Company” or “CPH”), a leading provider of concrete pumping and waste management services in the U.S. and U.K., reported financial results for the first quarter ended January 31, 2025. First Quarter Fiscal Year 2025 Summary vs. First Quarter of Fiscal Year 2024 (where applicable)  ● Revenue of $86.4 million compared to $97.7 million.  ● Gross profit of $31.2 million compared to $33.3 million.  ● Income from operations of $3.5 million compared to $1.5 million.  ● Net loss of $2.6 million compared to a net loss of $3.8 million.  ● Net loss attributable to common shareholders was $3.1 million, or $(0.06) per diluted share, compared to a net loss of...

LITTLE ROCK, Ark., March 11, 2025 (GLOBE NEWSWIRE) — Westrock Coffee Company (Nasdaq: WEST) (“Westrock Coffee” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided its outlook for 2025 and 2026. Full Year 2024 Highlights1Consolidated ResultsNet sales were $850.7 million, a decrease of 1.6% Gross profit was $153.8 million, an increase of 10.0% Net loss was $80.3 million compared to a net loss of $34.6 million in fiscal 2023 Consolidated Adjusted EBITDA2 was $47.2 million and included $12.8 million of scale-up costs associated with our Conway Facility, compared to Consolidated Adjusted EBITDA of $45.1 million and no scale-up costs associated with our Conway FacilitySegment ResultsBeverage SolutionsNet sales were $659.4 million, a decrease of 8.8% Segment...

Date: Friday, March 14, 2025Time: 2:00 p.m. (Eastern Time) NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) — You are invited to participate in TerraForm Power Operating, LLC’s Fourth Quarter and Full-Year 2024 Results Webcast and Conference Call on March 14, 2025 at 2:00 p.m. (Eastern Time) to discuss results and current business initiatives with senior management. These results will be made available on our website at www.terraform.com in the form of audited consolidated financial statements for the years ended December 31, 2024 and 2023 under “Financials” prior to the webcast and conference call. Participants can join by conference call or webcast: Conference Call Please pre-register by conference call clicking here Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. This process will bypass the...

Invests $54.5 Million in AI Infrastructure in 2024 CoreWeave, Inc., Single Largest Initial Investment in Fund’s History, Files for IPO Net Asset Value of $6.68 Per Share as of December 31, 2024 NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) — SuRo Capital Corp. (“SuRo Capital”, the “Company”, “we”, “us”, and “our”) (Nasdaq: SSSS) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2024. Net assets totaled approximately $157.6 million, or $6.68 per share, at December 31, 2024, as compared to $6.73 per share at September 30, 2024 and $7.99 per share at December 31, 2023. “Since inception, SuRo Capital has served as the public’s gateway to venture capital, offering unique access to some of the world’s most innovative and sought-after private companies before they become publicly traded....

Fourth Quarter Revenue Grew 6.8% Year-Over-Year to $44.2 Million, Including 91% Recurring Revenue GAAP Gross Margin Expands to 69.1%; Adjusted Gross Margin Rises to 79.3% Announced Three-Year Contract Extension with Major U.S. Telecom Provider in December Unveiled Capsyl, a Turn-Key Personal Cloud Solution for Global Operators, in March 2025 BRIDGEWATER, N.J., March 11, 2025 (GLOBE NEWSWIRE) — Synchronoss Technologies Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a global leader and innovator in Personal Cloud platforms, today reported financial results for its fourth quarter and full year ended December 31, 2024. Fourth Quarter and Recent Operational HighlightsReported total revenue of $44.2 million, driven primarily by 6.0% cloud subscriber growth year-over-year. Quarterly results included net income of $7.9 million,...

– Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 – – Anti-tau antibody VY7523 was well tolerated in healthy volunteers and showed dose-proportional pharmacokinetics; initial tau PET imaging data in Alzheimer’s patients expected H2 2026 – LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported fourth quarter and full year 2024 financial and operating results. “Over the past year, Voyager has significantly advanced our two wholly-owned programs targeting tau, which we view as the most important target in Alzheimer’s disease. Our anti-tau antibody VY7523...

Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H’26 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H’26 $357.0 million of cash provides runway into 2H’27 NEW YORK and WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the fourth quarter and full year ending December 31, 2024 and provided an update on recent business achievements. “We...